Replies to post #3936 on The Valens Company Inc. (VLNS)

[FUNMAN]

The Street may not appreciate the ER, but by 2022-06-30 ER the annual revenue run rate will be north of $120M

[FUNMAN]

B2C revenue lines of provincial sales and Green Roads accounted for ~50.0% of net revenue in Q3 2021

The really bad part of this statement is on the B2B extractor and B2B white labeling sides of the business, it doesn't appear that Valens is doing much better than MediPharm.

Valens is 50% reliant on organically growing through company owned brand/product line growth and acquisitions.

That means top line growth is going to be a long slow slog.

My shares can hang tough.

[FUNMAN]

The Street weighs in --->>> Price $1.73...Day's Change -0.14 (-7.49%)